quinazolines has been researched along with Hematologic Malignancies in 8 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 4 (50.00) | 29.6817 |
| 2010's | 3 (37.50) | 24.3611 |
| 2020's | 1 (12.50) | 2.80 |
| Authors | Studies |
|---|---|
| Dadwal, SS; Dickter, JK; Lee, BV; Ross, JA; Tegtmeier, BR; Zain, JM | 1 |
| Peggs, KS; Sellar, RS | 1 |
| Kitanaka, A; Shimoda, K | 1 |
| Botta, M; Brullo, C; Musumeci, F; Schenone, S | 1 |
| Thomas, NR | 1 |
| Hampton, T | 1 |
| Bonmassar, E; d'Amati, G; Graziani, G; Leonetti, C; Portarena, I; Scarsella, M; Tentori, L; Zupi, G | 1 |
3 review(s) available for quinazolines and Hematologic Malignancies
| Article | Year |
|---|---|
Therapeutic strategies for cytomegalovirus infection in haematopoietic transplant recipients: a focused update.
Topics: Acetates; Antiviral Agents; Benzimidazoles; Cytomegalovirus; Cytomegalovirus Infections; Cytosine; Hematologic Neoplasms; Hematopoietic Stem Cell Transplantation; Humans; Immunotherapy, Adoptive; Organophosphonates; Quinazolines; Ribonucleosides; T-Lymphocytes; Transplant Recipients; Transplantation, Homologous | 2014 |
Novel dual Src/Abl inhibitors for hematologic and solid malignancies.
Topics: Aniline Compounds; Animals; Antineoplastic Agents; Benzodioxoles; Clinical Trials as Topic; CSK Tyrosine-Protein Kinase; Dasatinib; Dogs; Drug Evaluation, Preclinical; Fusion Proteins, bcr-abl; Hematologic Neoplasms; Humans; Mice; Mice, Knockout; Mice, Nude; Mice, SCID; Neoplasms; Nitriles; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Quinazolines; Quinolines; Rats; src-Family Kinases; Thiazoles; Triazines | 2010 |
[Molecular target therapy for malignant tumors].
Topics: Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents; Benzamides; Clinical Trials as Topic; ErbB Receptors; Fusion Proteins, bcr-abl; Gefitinib; Hematologic Neoplasms; Humans; Imatinib Mesylate; Intracellular Signaling Peptides and Proteins; Neoplasms; Piperazines; Protein-Tyrosine Kinases; Pyrimidines; Quinazolines; Rituximab; Signal Transduction; Trastuzumab; Tretinoin | 2005 |
5 other study(ies) available for quinazolines and Hematologic Malignancies
| Article | Year |
|---|---|
Letermovir and maribavir for pan-resistant cytomegalovirus infection in a patient with haematologic malignancy: Consideration for combination therapy.
Topics: Acetates; Adult; Antiviral Agents; Benzimidazoles; Cytomegalovirus; Cytomegalovirus Infections; Hematologic Neoplasms; Hematopoietic Stem Cell Transplantation; Humans; Male; Quinazolines; Ribonucleosides | 2022 |
[Hematologic Malignancies/Pediatric Malignancies. II. Treatment of Essential Thrombocythemia--The Role of Anagrelide].
Topics: Child; Hematologic Neoplasms; Humans; Platelet Aggregation Inhibitors; Prognosis; Quinazolines; Thrombocythemia, Essential | 2016 |
Histone post-translational modification: from discovery to the clinic.
Topics: Acetylation; Animals; Antineoplastic Agents; Aurora Kinases; Benzamides; Clinical Trials as Topic; Depsipeptides; Hematologic Neoplasms; Histone Acetyltransferases; Histone Deacetylase Inhibitors; Histone Deacetylases; Histone Methyltransferases; Histone-Lysine N-Methyltransferase; Histones; Humans; Methylation; Protein Conformation; Protein Kinase Inhibitors; Protein Methyltransferases; Protein Processing, Post-Translational; Protein Serine-Threonine Kinases; Quinazolines | 2006 |
New blood cancer therapies under study.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents; Aurora Kinases; ErbB Receptors; Erlotinib Hydrochloride; Hematologic Neoplasms; Humans; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid; Myelodysplastic Syndromes; Piperazines; Protein Kinase Inhibitors; Protein Serine-Threonine Kinases; Quinazolines; Rituximab | 2007 |
Combined treatment with temozolomide and poly(ADP-ribose) polymerase inhibitor enhances survival of mice bearing hematologic malignancy at the central nervous system site.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Central Nervous System Neoplasms; Dacarbazine; Drug Evaluation, Preclinical; Hematologic Neoplasms; Male; Mice; Mice, Inbred C57BL; Mice, Inbred DBA; Poly(ADP-ribose) Polymerase Inhibitors; Quinazolines; Survival Analysis; Survival Rate; Temozolomide | 2002 |